|
gptkbp:instanceOf
|
gptkb:protein
|
|
gptkbp:alternativeName
|
gptkb:NARC-1
|
|
gptkbp:associatedWith
|
gptkb:cardiovascular_disease
gptkb:familial_hypercholesterolemia
gptkb:bococizumab
gptkb:lerodalcibep
gptkb:tafolecimab
|
|
gptkbp:binds
|
gptkb:LDL_receptor
|
|
gptkbp:cause
|
degradation of LDL receptor
|
|
gptkbp:discoveredBy
|
gptkb:Nabil_Seidah
|
|
gptkbp:discoveredIn
|
2003
|
|
gptkbp:encodedBy
|
gptkb:PCSK9_gene
|
|
gptkbp:Entrez_Gene_ID
|
255738
|
|
gptkbp:enzymeCommissionNumber
|
3.4.21.111
|
|
gptkbp:expressedIn
|
gptkb:kidney
central nervous system
liver
intestine
|
|
gptkbp:foundIn
|
gptkb:Homo_sapiens
|
|
gptkbp:fullName
|
gptkb:Proprotein_convertase_subtilisin/kexin_type_9
|
|
gptkbp:function
|
degradation of LDL receptor
regulation of cholesterol homeostasis
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PCSK9 protein
|
|
gptkbp:inhibitedBy
|
gptkb:alirocumab
gptkb:evolocumab
inclisiran
|
|
gptkbp:locatedOnChromosome
|
1p32.3
|
|
gptkbp:location
|
liver
extracellular space
|
|
gptkbp:molecularWeight
|
74 kDa
|
|
gptkbp:mutationAssociatedWith
|
loss-of-function mutations lower cholesterol
gain-of-function mutations cause hypercholesterolemia
|
|
gptkbp:OMIM
|
607786
|
|
gptkbp:PDB
|
gptkb:2P4E
|
|
gptkbp:postTranslationalModification
|
glycosylation
autocatalytic cleavage
|
|
gptkbp:regulates
|
LDL cholesterol levels
|
|
gptkbp:reviewedBy
|
gptkb:Nature
gptkb:science
gptkb:The_New_England_Journal_of_Medicine
|
|
gptkbp:structure
|
contains C-terminal domain
contains catalytic domain
|
|
gptkbp:target
|
gptkb:PCSK9_inhibitors
monoclonal antibodies
|
|
gptkbp:targetOfDrug
|
gptkb:familial_hypercholesterolemia
atherosclerotic cardiovascular disease
|
|
gptkbp:UniProtID
|
Q8NBP7
|
|
gptkbp:bfsParent
|
gptkb:Praluent
|
|
gptkbp:bfsLayer
|
6
|